Kiromic Biopharma, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Kiromic BioPharma, Inc. has filed for Chapter 7 bankruptcy, leading to the resignation of its board of directors and termination of key officers.
Kiromic BioPharma announces a significant cost-reduction measure by placing 31 employees on furlough, effective March 12, 2025, due to financial constraints.
Kiromic BioPharma issued a $1 million senior secured convertible promissory note to an accredited investor, with a 25% interest rate and potential conversion into common stock.
Kiromic BioPharma has entered into a material definitive agreement, issuing a $1 million senior secured convertible promissory note to an accredited investor to support its CAR-T cell therapy development and for general corporate purposes.
Kiromic BioPharma has entered into a $2 million financing agreement by issuing a senior secured convertible promissory note to an accredited investor.
Kiromic BioPharma has entered into an agreement to exchange $2.4 million in promissory notes plus accrued interest for preferred stock, reducing its debt by $3 million.
Kiromic BioPharma exchanged $2.4 million in promissory notes plus accrued interest for 3,000 shares of Series E Convertible Voting Preferred Stock.
Kiromic BioPharma has entered into a $2 million senior secured convertible promissory note agreement with an accredited investor, providing immediate capital and potential future equity conversion.
Kiromic BioPharma has entered into a $2 million senior secured convertible promissory note agreement with an accredited investor, providing the company with additional capital.
8-K: Kiromic BioPharma Holds 2024 Annual Meeting, Approves Key Proposals Including Reverse Stock Split
Kiromic BioPharma's 2024 Annual Meeting saw shareholders elect directors, ratify auditors, approve stock issuance, and authorize a reverse stock split.
Kiromic BioPharma has entered into an exchange agreement to reclassify $7.2 million in promissory notes and $1.6 million in accrued interest into preferred stock, and reclassify other accrued interest into a new convertible note.
Kiromic BioPharma has entered into a $2 million financing agreement by issuing a senior secured convertible promissory note to an accredited investor.
Kiromic BioPharma is leveraging its AI-driven platform and proprietary manufacturing capabilities to develop allogeneic Gamma Delta T-cell therapies for solid tumors, with promising early clinical results.
Kiromic BioPharma has entered into a $2 million senior secured convertible promissory note agreement with an accredited investor to fund its operations.
Kiromic BioPharma is leveraging its AI-driven platform and in-house manufacturing to develop allogeneic Gamma Delta T-cell therapies for solid tumors, with early clinical trial results showing promising safety and efficacy.
Kiromic BioPharma has entered into a $2 million senior secured convertible promissory note agreement with an accredited investor to support its ongoing operations and development.
Kiromic BioPharma has entered into an agreement to exchange $8 million of its senior secured convertible promissory notes for 8,000 shares of Series D Convertible Voting Preferred Stock.
Kiromic BioPharma has entered into a $2 million financing agreement by issuing a senior secured convertible promissory note to an accredited investor.
Kiromic BioPharma has entered into a $2 million financing agreement with an accredited investor through a senior secured convertible promissory note.
Kiromic BioPharma has entered into a $2 million financing agreement with an accredited investor through a senior secured convertible promissory note.